SCHEMBL10133727

SCHEMBL10133727

Cc1cc(NC=O)c2ccccc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
HTT P42858 2/20 0.57
MEN1 O00255 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GALR3 O60755 1/20 0.54
RAB9A P51151 1/20 0.54
CYP1A2 P05177 1/20 0.53
NCF1 P14598 3/20 0.52
NPC1 O15118 1/20 0.52
GUSB P08236 1/20 0.52
MAPT P10636 1/20 0.52
POLB P06746 2/20 0.51
OPRK1 P41145 1/20 0.51
LMNA P02545 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
RAD52 P43351 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28100413 0.81 SLC2A1 (0.46) KMT2AHTTMEN1SMN1; SMN2GALR3
SCHEMBL1980544 0.80 IGF1R (0.52) KMT2AHTTMEN1CYP2C19RAB9A
SCHEMBL10854774 0.80 POLB (0.48) KMT2AHTTMEN1L3MBTL1SMN1; SMN2
SCHEMBL1975113 0.80 NCF1 (0.51) KMT2AHTTSMN1; SMN2RAB9ANCF1
SCHEMBL1238925 0.79 CYP1A2 (0.60) KMT2AHTTMEN1L3MBTL1CYP2C19
SCHEMBL28193696 0.79 SLC2A1 (0.56) SMN1; SMN2LMNAKDM4E
SCHEMBL4903031 0.77 NQO2 (0.59) KMT2AHTTMEN1L3MBTL1CYP2C19
SCHEMBL6789826 0.77 CYP1A2 (0.58) KMT2AHTTMEN1L3MBTL1CYP2C19
SCHEMBL4855474 0.77 HTT (0.75) KMT2AHTTMEN1L3MBTL1CYP2C19
Hydrochloric Acid SCHEMBL4633833 0.76 L3MBTL1 (0.60) KMT2AHTTMEN1L3MBTL1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2768/4885HTT 1904/4885MEN1 2932/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2953/4885HTT 2095/4885MEN1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.